We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

New Drugs for Advanced Stage Pancreatic Cancer in the Pipeline

May 1, 1997
Volume: 
6
Issue: 
5
  • Gastrointestinal Cancer, Pancreatic Cancer

CHICAGO--After many years of frustration, there may finally be a reason
for guarded optimism about the development of effective therapy for patients
with advanced stage pancreatic cancer, Mace Rothenberg, MD, said at the
9th annual meeting of the Network for Oncology Communication and Research,
based in Atlanta.

One drug, gemcitabine (Gemzar), is now available that reduces the severity
of symptoms and another on the horizon may strengthen the effectiveness
of standard 5-fluorouracil (5-FU) treatment. Other drugs just entering
clinical trials may even prove to have a significant cytolytic effect on
pancreatic tumor cells.

In the first phase II trial of gemcitabine in 44 patients, the agent
had an objective response rate of only 11% but a 23% survival rate at one
year, which was higher than expected and considerably higher than the 2%
one-year survival seen with 5-FU, Dr. Rothenberg said. The agent alleviated
symptoms in 30% of patients.

Use of gemcitabine in a phase III trial of patients who had received
no prior treatment for pancreatic cancer also produced relatively low response
rates, but 18% were still alive after one year.

Furthermore, 24% of the patients had symptom relief, "which is
well out of proportion to the objective response activity," said Dr.
Rothenberg, associate professor of medicine, University of Texas Health
Sciences Center, San Antonio.

A third clinical trial in the United Kingdom had similar results--only
a 6% partial response rate but a 29% rate of symptom relief. "It's
a very convincing picture that, while this compound does not have much
impact in terms of radiographic appearance of pancreatic cancer, it is
having an impact on symptoms," he said.

The experimental drug 776C85, also known as 5-ethynyluracil, is particularly
exciting, he said, because it transforms "a clinically significant
problem associated with the use of 5-FU into a potential treatment weapon."
He explained that approximately 1% to 2% of cancer patients lack the enzyme
dihydropyrimidine dehydrogenase, which is the first enzyme in the degradation
pathway of 5-FU. Standard doses of 5-FU therefore are excessively toxic
to these patients.

By inhibiting the action of the dihy-dropyrimidine dehydrogenase enzyme,
776C85 enhances the activity of 5-FU. "The drug prolongs the half-life
of 5-FU from 15 minutes to 4½ hours, and may improve the antitumor
spectrum of 5-FU because it prevents the production of certain metabolites,"
he said.

While 776C85 alone had no direct antitumor effect on pancreatic cancer
in an experimental animal study, in combination with one-tenth the usual
dose of 5-FU, the drug was able to increase both the spectrum and bioactivity
of 5-FU.

Long-Acting Form of Octreotide

Just underway is a clinical trial of two agents that have shown a cytolytic
effect on pancreatic tumor cells in vitro--octreotide pamoate and gamcitabine.

Octreotide has been uniformly successful in killing pancreatic cancer
cells in lab studies but has been disappointing in clinical investigations,
probably due to an inability to achieve adequate plasma concentrations.
Octreotide pamoate is a long-acting form of the drug that may increase
plasma concentrations by as much as two to three logs.

The agent is being studied at the University of Texas, San Antonio,
in combination with gemcitabine to determine if the additive effects of
the two drugs seen against pancreatic cells in vitro can be duplicated
in phase II clinical trials.

Finally, he said, onconase, a chemical derived from frog eggs and embryos
that has been active against pancreatic cancer cells in the test tube,
is being evaluated in phase III trials as a possible front-line therapy
and as a second-line drug in patients who have received gemcitabine.

Related Articles

  • Inhibit CXCR4 to Treat CRC and Pancreatic Cancer
  • Short-Acting CCBs May Increase Risk of Pancreatic Cancer
  • A3AR Agonists May Help Prevent Chemotherapy-Induced Neuropathic Pain
  • Deep Learning–Based Tissue Analysis May Benefit Colorectal Cancer Patients
  • Napabucasin May Be Effective in Colorectal Tumors Positive for pSTAT3

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.